Zulu
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message

Submit An Free Inquiry

Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

AI Helps Write
AI Helps Write

Wang Liang

Isihloko: Udokotela Oyinhloko
Isikhundla: Inhloko Yesigaba
Iphrofayela Yomuntu Siqu: Udokotela Oyinhloko, uSolwazi, uMqondisi we-Ph.D., okwamanje unguMqondisi woMnyango We-Hematology weSibhedlela sasePeking Tongren. Waphothula ePeking Union Medical College ngo-2010, egxile kwezokwelapha emitholampilo ohlelweni lweminyaka eyisishiyagalombili, futhi wathola iziqu zobuDokotela Wezokwelapha. Ubelokhu ehilelekile ekuxilongeni nasekwelapheni izimila ze-hematologic (i-lymphoma, i-multiple myeloma, njll.) iminyaka engaphezu kwe-10, futhi unolwazi olucebile lwezokwelapha kanye nokufinyelela okuphezulu kwezemfundo ekuxilongeni nasekwelapheni izinhlobo ezahlukene ze-lymphomas kanye ne-myelomas, futhi ugxile ekwelashweni nge-immunotherapy okuqondiwe, i-chemotherapy, ukwelashwa ngamaseli e-CAR-T, ukufakelwa kwamaseli e-hematopoietic stem, kanye nokuhola ukuthuthukiswa kokuxilongwa nokwelashwa okuhlukahlukene (MDT). Izintshisekelo zakhe eziyinhloko zocwaningo ukuhlolwa kwe-immunotherapy okuqondiwe kanye nendlela yokumelana nemithi ye-lymphoma, futhi useke wengamela inqwaba ye-National Natural Science Foundation of China. Ushicilele amaphepha ochwepheshe angaphezu kuka-40, kufaka phakathi amaphepha angaphezu kuka-30 ane-SCI indexed, ashicilelwe ku-Lancet Haematology, Journal of Hematology & Oncology, Leukemia, Clinical Cancer Research, Cancer Treatment Reviews, Cancer Therapy Reviews, kanye namanye amaphephabhuku namajenali. Ushicilele ku-Lancet Haematology, Journal of Hematology & Oncology, Leukemia, Clinical Cancer Research, Cancer Treatment Reviews, Cancer, British Journal of Cancer, Annals of Hematology, kanye ne-Leukemia & Lymphoma. Ungumhleli ohlangene we-Standard Leukemia Diagnosis and Treatment, Standard Multiple Myeloma Diagnosis and Treatment, kanye ne-Medical Oncology. Wanikezwa umklomelo othi “Respect for Life-2017 Glory to Healers-Youth Innovation Award”, umklomelo othi “Tongren Elite” ngo-2020, umklomelo othi “Tongren Hospital Outstanding Young Talent” ngo-2020, kanye nomklomelo wokuqala othi “Tongren Hospital Outstanding Young Talent” ngo-2020. I-Tongren Hospital Outstanding Young Talent” ngo-2020, ‘35 Young Oncologists Under 35 with the Most Potential in China’. Izinhlangano Zezemfundo: Ilungu Elisha Legatsha Le-Hematology le-Chinese Medical Association; Ilungu Elisha Le-Lymphoma Immunotherapy Committee ye-Beijing Cancer Prevention and Control Society; Ilungu Elisha Le-Myeloma Committee ye-China Medical Education Association; Isazi se-National Natural Science Foundation of China. Ungumhleli ohlangene we-Aging Pathobiology and Therapeutics, ilungu lebhodi labahleli le-Chinese Journal of Cancer Prevention and Control, ilungu lebhodi labahleli elisha le-Concord Medical Journal, kanye nomhloli we-Journal of Hematology & Oncology kanye ne-Cancer Biology & Medicine.

Wang Liang